Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 458 |
| Active Pipeline (Recruiting Now) | 318 (143) |
| Completed vs Stopped Early | 52 / 88 (19.2%) |
| Median Closed Actual Enrollment | 23 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| NIH Clinical Center | Bethesda, MD | 181 |
| University of Oklahoma Health Sciences Center | Oklahoma City, OK | 173 |
| Washington University and Siteman Cancer Center | Saint Louis, MO | 140 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05886036 | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin L | Phase II | RECRUITING |
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Phase II | RECRUITING |
| NCT03606967 | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negativ | Phase II | RECRUITING |
| NCT04840602 | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) f | Phase II | RECRUITING |
| NCT07042295 | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the National Cancer Institute (NCI) Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.